Please visit answersincme.com/860/240201373-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Julie Stakiw, MD, FRCPC; and Constantine S. Tam, MBBS, MD. In this activity, experts in chronic lymphocytic leukemia (CLL) use case examples to discuss treatment management of high-risk CLL in both the frontline and relapsed/refractory settings. Upon completion of this activity, participants should be better able to: Identify high-risk chronic lymphocytic leukemia (CLL) based on cytogenetic, genomic, and clinical risk factors; Evaluate the latest clinical evidence informing the use of treatments for high-risk CLL in the frontline and relapsed/refractory (R/R) settings; and Apply guideline-concordant, evidence-based strategies to appropriately select and sequence treatments for high-risk CLL in the frontline and R/R settings.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related